详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Capilliposide B blocks VEGF-induced angiogenesis in vitro in primary human retinal microvascular endothelial cells.

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 预警期刊

作者：

机构： [a]College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou, 310027, PR China [b]Zhejiang-Malaysia Joint Research Center for Traditional Medicine, Zhejiang University, Hangzhou, 310027, PR China [c]Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA, USA [d]Department of Ophthalmology, Harvard Medical School, Boston, MA, USA [e]School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, PR China [f]Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 510005, Guangzhou, PR China [g]Shenzhen Eye Hospital, Shenzhen Eye Institute, Jinan University, Shenzhen, Guangdong Province, PR China

出处：

DOI：

ISSN：

摘要：

Abnormal angiogenesis is associated with intraocular diseases such as proliferative diabetic retinopathy and neovascular age-related macular degeneration, and current therapies for these eye diseases are not satisfactory. The purpose of this study was to determine whether capilliposide B (CPS-B), a novel oleanane triterpenoid saponin derived from Lysimachia capillipes Hemsl, can inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis signaling events and cellular responses in primary human retinal microvascular endothelial cells (HRECs). Our study revealed that the capilliposide B IC50 for HRECs was 8.5 μM at 72 h and that 1 μM capilliposide B specifically inhibited VEGF-induced activation of VEGFR2 and its downstream signaling enzymes Akt and Erk. In addition, we discovered that this chemical effectively blocked VEGF-stimulated proliferation, migration and tube formation of the HRECs, suggesting that capilliposide B is a promising prophylactic for angiogenesis-associated diseases such as proliferative diabetic retinopathy. Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区医学

小类 | 2 区药学 3 区医学：研究与实验

最新[2025]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 2 区药学

第一作者：

第一作者机构： [a]College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou, 310027, PR China [b]Zhejiang-Malaysia Joint Research Center for Traditional Medicine, Zhejiang University, Hangzhou, 310027, PR China [c]Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA, USA [d]Department of Ophthalmology, Harvard Medical School, Boston, MA, USA

共同第一作者：

通讯作者：

通讯机构： [a]College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou, 310027, PR China [b]Zhejiang-Malaysia Joint Research Center for Traditional Medicine, Zhejiang University, Hangzhou, 310027, PR China [g]Shenzhen Eye Hospital, Shenzhen Eye Institute, Jinan University, Shenzhen, Guangdong Province, PR China [*1]18 Zetian Road, Shenzhen Eye Hospital, Futian District, Shenzhen, Guangdong Province, PR China [*2]Zhejiang University, 148 Tianmushan Road, Hangzhou, Zhejiang Province, PR China

推荐引用方式(GB/T 7714)：

APA：

MLA：